Novo Nordisk's $1.4 Billion Bet That Pills Can Replace Needles

Novo's Shopping Spree Has a Theme

This deal doesn't exist in isolation. It's one tile in a mosaic Novo has been assembling over the past two years, and the pattern is unmistakable: oral drugs, next-gen mechanisms, and lots of zeroes.

Consider the recent deal flow. Novo licensed an oral GLP-1/GIP dual agonist from Hengrui Pharma for up to $2.6 billion (with $300 million upfront). It signed a collaboration with Septerna worth up to $2.2 billion for oral small molecules targeting GLP-1, GIP, and glucagon receptors. It grabbed a triple agonist from United Biotechnology for roughly $2.0 billion. And it picked up Nanexa's drug-delivery platform for up to about $1.3 billion to make injectables last longer.

Add in the Orbis deal and you're looking at a company that has committed billions in potential milestone payments across multiple external partnerships, all within a tight strategic window. Novo's own annual report frames these moves as a deliberate effort to "expand opportunities through strategic partnerships" and reduce its dependence on the semaglutide franchise (Ozempic, Wegovy).

In other words, Novo knows its crown jewels won't stay unique forever, so it's building the next generation before competitors can catch up.

Why Pills Are the New Battlefield

The injectable GLP-1 market (think Ozempic, Wegovy, Mounjaro) has been one of pharma's greatest success stories. But injectables have real-world limitations: cold chain storage, needle anxiety, clinic visits, patient dropout. Converting those therapies into pills could unlock entirely new patient populations, particularly the millions of people who need treatment but won't pick up a needle.

Novo already has a head start here. Oral semaglutide is the only oral GLP-1 on the market for type 2 diabetes.

But Eli Lilly is closing the gap fast. Its oral candidate orforglipron is a non-peptide small molecule in late-stage trials with a compelling profile: once-daily dosing, no food restrictions, no refrigeration needed. If orforglipron delivers strong phase 3 results, it could leapfrog oral semaglutide on convenience alone.

AstraZeneca has also entered the arena, licensing an oral once-daily GLP-1 candidate called ECC5004 for obesity, diabetes, and cardiometabolic conditions. The big pharma appetite for oral assets is real, and it's intensifying.

The Orbis Angle: Playing a Different Game

What makes the Orbis deal interesting is that it's not just about GLP-1 receptors. Orbis' macrocycle platform is designed to go after targets that conventional small molecules struggle to reach. The company describes its nCycles as capable of addressing both intracellular and extracellular targets, which opens up a broader set of cardiometabolic biology than the current GLP-1 fixation.

Orbis CEO Morten Graugaard called the agreement a "major partnership" and a validation of the company's platform. That's standard CEO-speak, but the subtext is real: when the world's largest obesity drugmaker writes you a check for discovery-stage work, it signals serious confidence in your technology.

For Novo, the bet is about optionality. These are early-stage programs; there's no guarantee any of them will produce a drug. But in a race where the winner gets to convert a $100 billion-plus injectable market into pills, paying for a seat at the table is cheap insurance.

The Bigger Picture

Pharma is in the middle of a format war, and the stakes are enormous. Injectable GLP-1s proved the biology works. Now the question is who can deliver that same biology in the most convenient package. Pills are the obvious answer, but making oral versions of complex biologics is notoriously difficult. That's why companies like Orbis, with purpose-built platforms for oral drug design, are suddenly very popular dance partners.

Novo Nordisk isn't waiting around to see who figures it out. It's placing bets across multiple partners, multiple mechanisms, and multiple modalities. The Orbis deal is the latest, and it won't be the last.

The injectable era of cardiometabolic medicine isn't over. But the companies building its replacement are getting funded at a pace that suggests the transition is closer than most people think.

$103M to Fix the Gene That's Slowly Destroying 1 in 1,000 Kidneys

A new biotech just emerged from stealth with $103 million to attempt something nobody has done: fix the broken genes behind the most common inherited kidney disease. The science comes from Yale, the money comes from RA Capital, and the stakes couldn't be higher.